65. Primary immunodeficiency Clinical trials / Disease details

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01461018 (ClinicalTrials.gov)	October 2011	24/10/2011	Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)	A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency	Primary Immune Deficiency	Biological: Immune globulin subcutaneous (Human)	CSL Behring	NULL	Completed	N/A	75 Years	Both	22	Phase 3	Japan
2	NCT01199705 (ClinicalTrials.gov)	September 2010	8/9/2010	Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)	A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency	Primary Immune Deficiency	Biological: Immune Globulin Subcutaneous (Human) (SCIG)	CSL Behring	NULL	Completed	N/A	75 Years	All	25	Phase 3	Japan
3	EUCTR2014-003409-13-Outside-EU/EEA (EUCTR)		05/01/2015	Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects with Primary Immunodeficiency (Japan Study)	A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects with Primary Immunodeficiency	Primary Immune Deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Hizentra® INN or Proposed INN: Human Normal Immunoglobulin Other descriptive name: Human Normal Immunoglobulin	CSL Behring	NULL	NA			Female: yes Male: yes	22		Japan